DECLARATION

I, Harshith k hereby declare that the Internship report entitled

“AN ORGANIZATION STUDY AT “STRIDES PHARMA SCIENCE
LIMITED” prepared by me under the guidance of Prof. Kishore M N, faculty of
MBA Department, K.S. School of Engineering and Management and external
assistance by Mrs. Shashikala , Sr, Manager-HR at Strides pharma limited,
Bengalore.

I also declare that this internship work is towards the partial fulfillment of the
university regulation for the award of degree of Master of Business Administration by
Visvesvaraya Technological University, Belgaum.

I have undergone an internship for a period for four weeks. I further declare that this
project is based on the original study undertaken by me and has not been submitted
for the award of any degree/diploma from any other University / Institution.

Place: HARSHITH K

Date: Signature of the student

The MBA course offered by Visvesvaraya Technological University has its own
unique syllabus which requires its MBA student to undertake an internship with any
of the leading business houses for a period ranging from 4 weeks during second
semester.

Strides Pharma limited is associate Indian pharma, headquatered at Bangalore in

southern Republic of India. The corporate manufactures pharmaceutical merchandise,
over-the-counter medication and nutraceuticals. The products of strides limited are
categorized into three categories (1) Pharma generic, (2) Branded generic, (3)
Institutional business. The list of product produced under (1) pharma generic such as
General tablets, Hard Gelatin capsules, Soft gelatin Capsules, Potent drugs, Sachets,
ointments, Semi solids, dry and wet injectables, and Creams. Some of the products
produced under (2) Branded generic are Amlostar, Salazi, CLO-BKO.
Some of the pharma generic products are mainly processed in North America, Europe,
Australia. The corporate has fifteen producing sites in six countries and selling
presence in fifty (50) countries. within the US and Canadian markets, the corporate
partners with generic firms to provide retail and hospital generic in injectables
merchandise and soft gels. In European markets, its long relationships for the event
of comes and provide agreement with the firms, In Australia and New island, the
corporate has development and provide agreements with South African firms. the
company stocks trades on the urban center exchange and on the national exchange of
Republic of India.

This report describes and discusses the types if risks that are faced, the ways that
various risks can be assessed and managed and how corporate resources can be
allocated to meet the goals and to create maximum value according to the corporate
strategy. The details of the report describes the various products and services
produced and various drug formulation strategy used in development if tablets, the
organization has its own vision mission and quality policy. The other part of the
report details about the analysis of the financial statements such as ratio and trend
analysis. As per the analysis the overall company’s performance is good and
satisfactory.
 CHAPTER – 01

INTRODUCTION ABOUT

INTERNSHIP,

INDUSTRY PROFILE.
 INTRODUCTION ABOUT THE INTERNSHIP, INDUSTRY
PROFILE

1. INTRODUCTION
An internship is duration of work expertise propounded by a company for a finite
amount of your time.

It’s a chance offered by Associate in nursing leader to potential worker, referred to as

interns throughout the course of their study.

They’re sometimes undertaken by student and graduates trying to get relevant skills
and skill in an exceedingly specific field. The intern’s position is temporary with a
stress on on-the-job coaching instead of simply employment, and it is paid or unpaid.

An internship consists of Associate in Nursing exchange of services for expertise

between the intern and also the organization it creates knowledgeable network that
may assist with letter of advice or result in future employment opportunities.

It renders student the power to participate in an exceedingly field of their option to

receive hands on learning a few specific future careers, getting ready them for full-
time work and support your transition from “Classroom to Corporate”.

It provides employment to millions and ensure that essential drugs at affordable price
are available to the vast population of India.

Health is defined both as a cause and effort of economic development. Therefore

pharmaceutical industry

Is defined as an essential factor that can contribute to the economic development.

In addition it provides

Significant socio economic benefits to the society through creation of jobs, supply
chains and through community development.

The industry also plays an important role in the technological innovation which may
reduce the cost of economic activity elsewhere in the economy players in the
pharmaceutical industry.

Include branded drug manufacture, generic drug manufactures, firms developing bio-
pharmaceutical products, non-prescription drug manufactures.

Contribution of Strides pharma is in manufacturing of drugs . Indian pharmaceutical

Industry is playing a key role

In promoting and sustaining development in the vital field of medicines. Around 70%
of the country’s
Demand for bulk drugs, drug intermediates, pharmaceutical formulation, chemicals,
tablets, capsules, orals and vaccines is met by Indian pharmaceutical industry.

Pharmaceutical Industry in India is one of the largest and most advanced among the
developing countries.

1.1 INDUSTRY PROFILE

The Indian Pharmaceutical trade is presently valued at `720.69 bn as against `656.54
bn in 2012, up by 9.8% YoY. The main factors liable for this growth are increasing
sales of generic medicines, continued growth in chronic therapies and larger
penetration in rural markets. The Indian Pharmaceutical trade is globally the third
biggest in terms of volume with a tenth share. Republic of India spends simply
one.4% of its total gross domestic product on healthcare; the country ranks amongst
very cheap during this respect. In distinction, the corresponding figure for developed
countries is in far more than vi.5-8% of gross domestic product. It’s foreseen that the
Indian prescription drugs market can grow to USD fifty five bn in 2020; and if
aggressive growth methods are enforced, it additional has potential to succeed in USD
seventy bn by 2020.

The India pharmaceutical trade is principally operated additionally as controlled by

the dominant foreign firms having subsidiaries in India because of the provision of
low-cost labour in India. The trade is extremely fragmented with regarding 24,000
players.

Indian pharmaceutical sector trade provides over fifty per cent of worldwide demand
for numerous vaccines, forty per cent of generic demand within the North American
country and twenty five per cent of all medication in GB. Asian nation contributes the
second largest share of pharmaceutical and biotech personnel within the world. In
March 2018, the Indian pharmaceutical market grew at 9.5% year-on-year.

With seventy one per cent market share, generic medication types the most important
section of the Indian pharmaceutical sector. Asian nation has become the third largest
international generic API businessperson market by 2018, with a 10.2 per cent market
share.

The country accounts for the second largest range of Abbreviated New Drug
Applications (ANDAs) and is that the world’s leader in Drug Master Files (DMFs)
applications with the North American country Indian medication and prescription
drugs sector has received additive FDI price US$ 15.59 billion between Gregorian
calendar month 2000 – Dec 2017.

Indian medication are exported to over two hundred countries within the world, with
the United States of America because the key market. Generic medication account for
twenty per cent of world exports in terms of volume, creating the country the most
important supplier of generic medicines globally and expected to expand even any in
coming back years. The Indian pharmaceuticals exports stood at US$ 17.27 billion in
2017-18.

The Government of India plans to line up a US$ 640 million working capital fund to
spice up drug discovery and strengthen pharmaceutical infrastructure. The ‘Pharma
Vision 2020’ by the government’s department of prescribed drugs aims to create India
a serious hub for end-to-end drug discovery.

Even in these circumstances, the trade has mature price with a median annual rate of
6-7 % over the last 5years.

Indian pharmacy industry ranks 17th in terms of export value of bulk actives and
dosage forms. Indian exports are exported to more than 200 countries around the
globe including highly regulated markets of US, Europe, Japan and Australia. It is one
of the few industries which is export surplus i.e. exports of pharmaceutical products
are higher in value than imports of pharmaceutical products. Also, it is one of the few
industries in India not greatly impacted by the current global economics laid down.

The first Indian pharmaceutical company, Bengal chemicals and pharmaceutical

works, which still exists today as one of 5 government- owned drug manufactures,
appeared in Calcutta in 1930.

These five public sector drug manufacturing units under the Ministry of Chemicals
and Fertilizers are

 Indian Drugs and Pharmaceutical Limited (IDPL)

 Hindustan Antibiotics Limited (HAL)
 Bengal Chemical and Pharmaceutical Limited (BCPL)
 Smith Stanistreet Pharmaceutical Limited (SSPL)

In addition, there are a number of pharmaceutical manufacturing units under the

control of state governments such as Goa Antibiotics Ltd, Karnataka Antibiotics Ltd.
Fro the last 60 years, most of the drugs in India were imported by multinational either
in fully-formulated or bulk form. There are 24000 licensed pharmaceutical
companies. Of the 465 bulk drugs used in India, approximately 425 are manufactured
here.

India has more drug manufacturing facilities that have been approved by the U.S.
Food and Drug Administration than county other than the US. Indian generics
companies supply 84% of the AIDS drugs that Doctors without Borders uses to treat
60000 patients in more than 30 countries .

The Indian pharmaceutical industry currently tops the chart amongst India’s science
based industries with wide ranging capabilities in the complex field of drug
manufacture and technology.
A highly organized sector , the Indian pharmaceutical Industry is estimated to be
worth $ 6 billion , growing at about 10% annually. It ranks very high amongst all the
third world countries, in terms of technology, quality and the vast range of medicines
that are manufactured. It ranges from simple headache pills to sophisticated
antibiotics and complex cardic compounds almost every type of medicine is now
made in the Indian pharmaceutical industry. The Indian pharmaceutical sector has
expanded drastically in the last two decades. The pharmaceutical industry in India is
an extremely fragmented market with severe price competition and government price
control. There pharmaceutical industry in India meets around 90% of the country’s
demand for bulk drugs, drug intermediates, pharmaceutical formulation, chemicals,
tablets, capsules, orals and injectables. There are approximately 300 big and medium
scale units, which form the core of the pharmaceutical industry in India.

In future it will be a growth period of Indian Pharmaceutical Industry. The growth is

expected to emerge from three major areas:

 contract research and development services,

 Export led business of generics and bulk drugs
 Growth in specialty therapeutic areas in the domestic market.

The growth in the institutional segment is likely to raise the market for diagnostics.
Increasing industrialization, literacy levels and urbanization are likely to increase the
health awareness of the general public. Consequently the demand for preventive
medicine in general and immunological like tetanus toxoid, triple antigen (DPT),
measles vaccine are likely to increase. Companies are likely to pay greater attention
to their human resources development effort in general and management
developmental programs in particular. The present state of armed truce between the
trade and the industry is likely to continue in the future. The industry is likely to be
united more closely the before. Companies which have strong research. focus and
competence only, can achieve a sustainable growth and development. Companies that
think steadily increasing their investment in Research and Development.

This has been driven by the subsequent sanctionative factors:

 Increasing demand in international markets: Generic penetration in high price

health care markets (e.g., US) has adult considerably, with Bharat supply 20+
% of the generics demand in major geographies.

 Stable growth in domestic market consumption: India’s pharmaceutical market

has adult apace over the last decade. Despite recent headwinds, a stable
growth to 5-7% was last year. India is probably going to become one in all the
highest three company markets by 2030.
  Low price and at scale producing capability in India: India has the second
highest range of America office approved facilities and labour prices in Indian
are nonot up to alternative producing hubs by up to 40% .

PHARMACEUTICAL INDUSTRY IN INDIA

The Indian Pharmaceutical industry was valued at USD 33 Billion in 2017. The
exports from India alone stood at USD 17.27 Billion. The industry is expected to
grow at a CAGR of 22.4% between 2015- 2020 and achieve a market size of USD 55
Billion, of which the domestic generic market is expected to contribute USD 27.9
Billion. India has also become a popular destination for outsourced contract research
and manufacturing service. The contract manufacturing and research Industry is
expected to have grown at 18-20 % CAGR in 2018, and is expected to have a market
size of USD 18 Billion.

The industry is typically involved in four types of businesses- marketing of generic

medicines, marketing of branded generic medicines, marketing of innovator
medicines, and manufacture and supply of active pharmaceutical ingredients which
are used as ingredients in medicines as well as finished formulations.

However, the industry is primarily focused on manufacturing of generic medicine

and export of bulk drugs. The focus on development of new drugs began only with
introduction of new Patent regime in 2005 which permitted patenting of
pharmaceutical products. Thus, while many domestic companies are investing
substantial amounts in drug research and development, India is still not an innovator’s
market.

The Indian Pharmaceutical industry is witnessing healthy foreign direct investment,

amalgamations and collaborations (such as licensing, co- development, joint
distribution and joint ventures). Domestic manufacturers are looking to tap into
international generic market with high margins. The Abbreviated New Drug
Applications (ANDA) to the US FDA is increasing every year. The Industry is
witnessing a paradigm shift as the focus is shifting from the manufacturing of generic
drugs to drug discovery and development (Sun Pharma, Cadilla Healthcare and
Piramal Life Sciences, had applied for conducting clinical trials on for numerous new
drugs).) The clinical trials industry is also growing steadily after witnessing a brief
lull due to regulatory issues such as delay in obtaining approvals, compensation issues
etc. which have since been clarified and resolved by the concerned regulatory
authority.

As the pharmaceutical industry operates in the sensitive health sector, there are a
plethora of laws which regulate it. Right from manufacture of drugs to advertisement
and promotion, each step in drug manufacturing and marketing process is regulated.
As mentioned earlier, India introduced a patent protection regime in 2005 to protect
both process as well as product innovation. India now also has its own competition
law to address anti-trust issues which arise in course of day to day operation of the
industry as well as owing to the numerous collaborations which the Industry is
witnessing.

The industry has witnessed numerous changes in the regulatory regime in the recent
past. A new price control order has been enforced and prices of all essential medicines
under the National List of Essential Medicines, 2015 have been brought under price
control. India has implemented a compulsory primary, secondary and tertiary
barcoding requirement on all its exports in a phased manner. A new compensation
regime has been introduced for clinical trial subjects wherein grounds for
compensation have been specified. A voluntary uniform code for marketing practices
of pharmaceutical companies was introduced sometime back to check improper
promotions of drugs before medical practitioners. A large number of fixed dose
combination drugs have been banned due to their unapproved use. Backed by a
strong intellectual property and regulatory framework, the Indian pharmaceutical
industry seems poised to achieve greater heights.

Indian pharmaceutical industry has been witnessing significant growth over past few
years. The size of the Indian pharmaceutical market increased from USD 6 Billion in
2005 to USD 33 Billion in 2017.5 By 2020, India’s pharmaceuticals market is
expected to reach USD 55 Billion and become one of the largest pharmaceutical
market in the world. The pharmaceuticals sector has attracted FDI worth USD 15.72
Billion between April 2000 and March 2018, according to data published by
Department of Industrial Policy and Promotion (DIPP). The Government also has
plans to set up a US$ 700 million venture capital (VC) fund to give a boost to drug
discovery and strengthen the pharma infrastructure in the country. The Indian
Government, in efforts to boost R&D in the pharmaceutical sector, has established six
National Institutes of Pharmaceutical Education and Research (NIPER) and declared
them as ‘Institute of National Importance.

For a global pharmaceutical company seeking to enter Indian pharmaceutical market

today, the opportunities are exciting and the potential is tremendous.

Several factors attract global pharmaceutical companies to India:

 Low cost of production due to variety of factors including cheap labor and raw
material cost;
 Big market not only for life saving drugs but also for lifestyle drugs;
 Potential for conducting research and development activities in India – India
has more than 300 medical colleges, over 20,000 hospitals;
  Existing manufacturing capability to produce active pharmaceutical
ingredients (APIs) as well as intermediates at lower cost while maintaining
quality.
 India has maximum number of USFDA approved plants outside USA which
are over 16910 in number.
 Ease of conducting clinical trials and bio availability and bioequivalence
studies due to India’s ability to provide speedier and less expensive trials
without compromising quality and vast patient pool;
 Product patent regime;

FOLLOWING ARE THE ADVANTAGES OF INDIAN

HEALTHCARE SCENARIO:
 Competent workforce:

India possesses a skilful work force with high managerial and technical competence.

 Cost-effective chemical synthesis:

The track record for development, particularly in the area of improved cost-beneficial
chemicals synthesis for various drug molecules is excellent.

 Legal and Financial Framework:

India is democratic country with a solid legal framework and strong financial markets.

There is already an established international industry and business community.

 Information and Technology.

It has good network of world-class educational institutions and established strengths

in Information Technology.

DEVELOPMENT OF INDIA’S PHARMACEUTICAL INDUSTRY:

Till 1970s, India’s pharmaceutical market was mainly supplied by large international
corporations. Only economical bulk drugs were produced domestically by state-
owned founded in the 1950’s and 60s with the help of the World Organization
(WHO).

These state-run firms provided the foundation for the sector’s growth since the 1970s.
Back then , Indian government aimed to reduce the country’s strong dependence
pharmaceutical imports by flexible patent legislation and to create a self-reliant sector.

In addition, it introduced high tariffs and limits on imported medicines and demanded
that foreign pharmaceutical companies reduce their shares in their Indian subsidiaries
to two-fifths.
Large Market share for Generic Drugs As there was no efficient patent protection
between 1970 and 2005; many Indian drug producers copied expensive original
preparations by foreign firms and produced these generics by means of alternative
production procedures.

This proved more cost efficient than the expensive development of original
preparations as no funds were required for research, which contained the financial
risks. This spending may come to as much as EUR 600 m for only one drug. This
kind of money could previously only be raised by large corporations in the industrial
corporation in the industrial countries.

The competitiveness of generic producers is based on cost-efficient production. In this

field, Indian companies are currently in top position.

At one-fifth, India’s share in the global market of generic drugs is considerably higher
than its share in the overall pharmaceutical market (apporx.20%). At the same time,
India’s pharmaceutical companies gained know-how in the manufacture of generic
drugs.

Hence the name “pharmaceutical of the poor” which is frequently applied to India.
This is of significance for the domestic market as disposable income is as little as
EUR 1900 per year for roughly 140 million of the total of 192 million Indian
households, which means the majority of Indians, cannot afford expensive western
preparations.
 CHAPTER – 2
ORGANIZATIONAL
PROFILE
 2. ORGANIZATION PROFILE

2.1 BACKGROUND
Strides Pharma Science Limited, incorporated in 1990, is a pharmaceutical
company headquartered in Bangalore, India.

The company is listed on the Bombay Stock Exchange and National Stock
Exchange of India Limited. Strides is engaged in the development, manufacture,
and marketing of pharmaceutical products for regulated and emerging markets.

It has seven manufacturing facilities including four US Food and Drug

Administration approved facilities and two facilities for emerging markets. Strides
also has in-house R&D infrastructure in India.

TYPE MNC (several JVs, and subsidiaries)

INDUSTRY PHARMACEUTICAL

FOUNDED 1990

FOUNDER ARUN KUMAR

SERVED
NORTH AMERICA
AUSTRALIA
AFRICA
UK
INSTITUTIONAL BUSINESS

EMPLOYEES APPROXIMATELY 2000

PARENT STRIDES PHARMA SCIENCE

LIMITED

WEBSITE WWW.STRIDES .COM

Strides Pharma Science Limited is an integrated manufacturer and exporter of

finished pharmaceutical dosage forms for both branded and generic.

The company manufactures a very wide spectrum of ethical pharmaceutical products

OTC products and nutraceuticals.
The products of strides limited are categorized into three categories (1) Pharma
generic, (2) Branded generic, (3) Institutional business.

The list of product produced under (1) pharma generic such as General tablets, Hard
Gelatin capsules, Soft gelatin Capsules, Potent drugs, Sachets, ointments, Semi solids,
dry and wet injectables, and Creams.

Some of the products produced under (2) Branded generic are Amlostar, Salazi, CLO-
BKO.
Its soft gel producing capability consists of associate annual capability of 50,000
machine hours or concerning 3 billion soft gel capsules.

The corporate has fifteen producing sites in six countries and selling presence in fifty
countries. Within the US and Canadian markets, the corporate partners with generic
firms to provide retail and hospital generics in injectable merchandise and soft gels. In
European markets, its long relationships for the event of comes and provide
agreements with the firms.

In Australia and New Island, the corporate is engaged in producing and provide of
soppy gels and added producing. The corporate has development and provide
agreements with South African firms. The company's stock trades on the urban centre
exchange and on the National exchange of Republic of India.

Strides Shasun restricted was uniting with Shasun prescription drugs with Strides
Arcolab. In September 2014, the Board of administrators of each had approved a
theme of uniting between the two companies.

In 2018 Strides Shasun limited becomes Strides Pharma Science Limited.

Arun Kumar is that the founder and Chairman, and has been on the Board of Director
since its origin.

The company also owns two dedicated production facilities for the emerging
markets. As at March 31 2018 the company had 51 subsidiaries (46 overseas and 5 in
India) 3 Joint Ventures (2 overseas and 1 in India) and 4 associate companies (3
overseas and 1 in India).
Strides Pharma Science Limited was originally incorporated under the name Strides
Arcolab Ltd in the year 1990.

In FY 2016 Shasun Pharmaceuticals Limited successfully completed the merger with

Strides Arcolab forming the new identity Strides Shasun Limited effective from 19
November 2015.

The name of the company was changed to Strides Pharma Science Limited effective
July 18 2018.
Strides Arcolab Ltd is among the top-15 pharmaceutical companies of India. They are
among the world's top 5 soft gelatin capsule manufacturers.

They have partnership agreements with more than 10 of the top-50 global
pharmaceutical majors across Australia South Africa the EU and the USA.

They have their marketing presence in 55 countries.

Initial foray as an emerging market FDF company with third party manufacturing
1994-03 - Foray into Specialised manufacturing

Commenced manufacturing of sterile’s, soft-gel capsules, ARVs and anti-TB drugs

2004-08 - Front-end acquisitions and R&D pipeline

Acquisition of front-end platforms in SE Asia, Australia and India

2008-12 - Regulated markets focus

Partnerships with global pharmaceutical companies for regulated markets

2012-13 - Value creation in Strides 1.0

- Sale of Branded generics business in Australia (Ascent)

Sale to Watson for A$375 million in 2012

-Sale of Specialty injectables(Operated as Agila)

Sale to Mylan for enterprise value of up to US$1.75 billion in 2013

Distributed dividends @ INR 605/share in FY14 and FY15; Total pay-out of US$655
million
2014- Current - Rebuilding capabilities and Scale in Strides 2.0

Merger with Shasun for pipeline and supply chain security

Re-entered (Merger) with Australia through Arrow. Bolt on acquisitions of Generic

Partners ,Pharmacy Alliance

Acquisition of Universal Pharma in Kenya for African business

Re-established R&D base(Previous R&D was part of Agila divestments to Mylan)

Acquisitions in US and Australia for new products

JV with Vivimed for pipeline and US FDA formulations facility

Divestment of India branded business to Eris Life Science for Rs 5,000 million

Demerger of Human commodity API business to Solara Active Pharma Sciences

Foray into South Africa (Trinity)
Proposed merger with Apotex (Arrow) in Australia to become a leading player
(Subject to regulatory approvals)

In 2018, Strides also announced its intent to merge Arrow with Apotex's(Arrow) Australian
business. The deal closure is subject to regulatory approvals.

Business segment:
Regulated markets

 Front-end presence across Australia, the US and UK.

 Five facilities [Four USFDA approved] in India, Europe and Singapore.

Emerging markets

 Front-end focused markets of Africa, Southeast Asia with a portfolio of branded

generics
 Two manufacturing facilities dedicated for emerging market operations – One
facility at Universal Corporation, Kenya and one manufacturing facility
in Bengaluru, India
 Catering to donor-funded programmes using the local facility in Africa.

Key Market Operation

North America
Strides Pharma Inc. is front-end company for Strides’s operations in the US.
Strides re-entered the US market in 2015 post the divestment of its
Specialty injectables franchisee- Agila to Mylan Inc. Its focus is mainly on niche, low
volume, low competition, high technology barrier products built around Modified
Releases, soft-gel capsules (SGCs), topicals and liquids. In the Consumer Healthcare
space, Strides operate both in Brands as well as Private Labels and its key brands
include JointFlex, Vanquish, Pediacare and Fergon. At the end of July 2018, Strides
had a portfolio of 78 filed ANDAs with 51 product approvals.

Australia
Strides is one of the early entrants to the market through Ascent Pharma, which in the
year 2012, was acquired by Watson Pharmaceuticals. Strides re-entered the market in
2015 as Arrow Pharmaceuticals(Arrow) and is amongst the top 3 generics companies
of Australia. Arrow has a nationwide sales presence, driving distribution and loyalty
in generics and its proprietary "Chemist’s Own" over-the-counter (OTC) portfolio. It
sells over 190 molecules with a pharmacy coverage of 1,400+ stores and 4,000+
pharmacy accounts.
Africa
Strides business activities in this continent are driven by the philosophy of
“In Africa for Africa” which it bolstered with the acquisition of a WHO-approved
facility under Universal Corporations in Kenya. Strides has a significant sales
footprint in 40+ African countries with a robust medical field force in Africa that
helps extend reach to 30,000 doctors.

UK
Strides operates in the UK through its step down wholly owned subsidiary Strides
Pharma UK Ltd, who have been reliably supplying high-quality generics to Tier 1 &
Tier 2 wholesalers in the retail sector as well as the NHS through Commercial
Medicines Unit tenders.

Institutional business
Strides is an approved supplier to institutionally funded aid projects and
Global Procurement Agencies like USAID, Global Fund, PEPFAR (The US
President’s Emergency Plan for AIDSRelief), UNICEF, WHO, Pan American Health
Organization (PAHO), United Nations Development Program (UNDP), Population
Services International (PSI), Chemeonics, PFSCM, amongst others. Its products are
supplied to disease-prone regions in Africa, Asia and Latin America with distribution
to several areas.

Manufacturing facilities in india and overseas :

Strides has a global manufacturing footprint with seven production units spread across
three continents. Five of its manufacturing facilities cater to regulated markets have
key regulatory approvals
including USFDA, UK MHRA, TGA, PMDA ANVISA, WHO. The Company also
own two dedicated production facilities for the emerging markets
at Kenya and Bengaluru, India.

Research and Development in Bengalore, India:

Strides is led and driven by its expertise in Research and Development, visible
through its success in creating niche and differentiated products portfolio. Its Global
Formulation R&D centre at Bangalore drives high value product delivery via latest
technology platforms.
2.2NATURE OF BUSINESS (MANUFACTURING)
 It is one of the leading manufacturing of generic drugs in the unites States.
The firm produces and markets numerous generic and proprietary (brand-
name) drugs, with the sale providing 80 percent of total revenues.
 Generic operations are conducted through 4 stages subsidiaries. Granulation
is the first dispensing of material will take place then shifting of the material.
Compression is a second stage where granulated materials are compressed into
required size later on it will be bunched with required size of the tablet.
Coating is third stage done for various reasons to add flavor t the tablet and by
giving is fourth stage Packing is done to protect the tablets from temperature
and moisture present in the environment. Labelling is the fifth stage the ensure
optimal functioning and reduce the amount of time spent on support activities.
 The decision to integrate the ASRS in both the warehouse and manufacturing
areas was not only logistical challenge, but a software challenge as well.
Distinct software packages-SAP, software for the weighing machines, in-
boarding document from the vendor – had to be combined and integrated so
that each program could communicate with complete product information at
all times.

2.3VISION, MISSION AND QUALITY POLICY

VISION

To be a profitable provider of high quality products and solutions that create strategic
value to their partners and provide as safe, healthy and rewarding work place for their
employees.
The company will achieve its growth by continuing to develop its existing markets
and grow globally.
It does this it will seek out to create lasting partnership with local expertise and talent.
It will strive to serve local market with its own distinct requirement to a large extent
by its own people.
The company will share the cultures and values of its partners and customers
Winning together – is an earnest initiative that aims to make persuasive and
systematic contribution beyond Strides, in the areas of healthcare, community service
and social development,
Environment health and Safety projects our focus is in identifying the areas of
development and improvement with total transparency and share values
MISSION

As we stretch ourselves globally, our success depends on the strengths of our local
partnership

The mission statement basically answer one question-how do we intend to succeed in

business.
The mission statement balances the possible and impossible
Mission statement gibes a clear sense of direction and inspiration to make us feel a
part of something Big and Important.

QUALITY POLICY

 To fabricate and supply products and services steady with universal

requirements in the direction of general consumer delight
 To create in any respect ranges an surrounding to sell first class as a manner
of existence with a strong sense of values and dedication
 To constantly teach employees, improve machinery, processes and facilities
towards productiveness and steady excellent of services and products.
 Being responsive to external and internal issues which influence learn work
and performance.
 To conduct professionally with shareholders, employees, customers,
suppliers, financial institutions, government and the public
 To practice quality system confirming to ISO: 9001.

2.4 PRODUCT / SERVICE PROFILE

The products of strides limited are categorized into three:

 Pharma generic
 Branded generic
 Institutional business

List of products: under pharma generic

 General Tablets
 Hard Gelatin Capsules
 Soft Gelatin Capsules
 Potent drugs
 Sachets
  Ointments
 Semi solids
 Creams

Some of the products under branded generics are as follows:

 Amlostar
 Salazi
 CLO-BKO

Some of the pharma generic products are mainly processed in the following
regions

 North America
 Europe
 Australia

Fighting AIDS
AIDS may be a leading reason behind death
globally. AN calculable thirty four million
individuals were living with HIV worldwide in
2012, with simple fraction living in geographic
region. whereas this reflects the continuing
sizable amount of latest HIV infections, there's
a major increase in access to effective and cheap antiretroviral therapies (ART)
that has helped scale back AIDS-related deaths.
While Strides encompasses the world necessities of ART, the main target is on
production and provide of newer anti-retroviral medicine that are tough to
manufacture. This includes medicine dispersible formulations, new fixed-dose
molecules (Products that are still below patent) that Strides have access through
license agreements with Gilead, Vive health care, among others, for the
underdeveloped & developing markets.

Fighting TB

Second solely to AIDS, TB is to blame for

majority of deaths from Associate in Nursing
communicable disease globally. Worldwide,
mortality from TB has fallen by forty one %
since 1990. Despite this progress, the world
burden of TB remains monumental.
However, recent years have seen a rise within
the range of TB patients diagnosed with multidrug-resistant TB, burning by the
HIV epidemic, notably in geographic region. People who are HIV-positive are up
to thirty times a lot of probably to develop active TB than people who aren't.
Strides features a progressive anti-TB drug facility formulating the varied fixed-dose
mixtures necessary to tackle the ill-famed malady each for affected adults yet as
medicine populations. So authorised to combat resistant styles of TB yet as HIV-TB
co-infection and preventing any unfold of the malady.

Fighting Malaria

As of 2012, 3.3 billion sleep in areas in

danger of protozoal infection transmission in
106 countries and territories. 781,000
individuals die of protozoal infection per
annum and it affects the foremost vulnerable.
Over eightieth of those deaths are in Africa
alone. Besides lost economic output, fortieth of drug expenditure in affected
countries is spent on protozoal infection medicine alone.
Strides have begun offer of United Nations agency Pre-Qualified Artemether +
Lumifantrine (AL) Tablets and Artemether in to the affected populations. The API for
anti-malarial medicine is sourced from Sequent Scientific restricted, that works
closely with the Strides cluster. For Artemether, they're backwardly integrated up to
the farm wherever artemisinin is extracted from shrub plants. Strides can shortly
introduce paediatric dispersible formulations of anti-malarial to cater to protozoal
infection infected infants and youngsters. Keeping in synchronise with the most recent
treatment pointers, Strides appearance forward to introduce newer merchandise and
meet rising demand.

Products associated with Strides shasun Ltd

Cognitin Capsule Diazox Liniment

Cognix 200mg Injection Diazox MR 250 mg/50 mg/500 mg
Cognix 500mg/5ml Syrup Tablet
Cognix Plus Tablet Diazox SF 50 mg/500 mg/10 mg
Cognix Tablet Tablet
Complatt 75mg/75mg Tablet Dismol DP 10 mg/325 mg/37.5 mg
Complatt Forte 150mg/75mg Tablet Tablet
Confilev 250mg Tablet Dismol P 500 mg/50 mg Injection
Confilev 500mg Tablet Dismol P 500 mg/50 mg Tablet
Constipeg Sachet Lemon Diznil 25mg Tablet
Constipeg Tablet Diznil 75mg Tablet
Crystcare 40mg Tablet Dubix-K Tablet
Crystcare 80mg Tablet Elzinex 5mg Tablet
D Bright 400IU Drop Encremin Capsule
D Bright 60K Capsule
D Con 10mg Tablet
D Con 5mg Tablet
D Met 250mg Tablet
D Met 500mg Tablet
D Met 500mg Tablet SR
D Met 850mg Tablet
D-Clic 40mg Tablet
D-Clic 80mg Tablet
D-Glip 2.5mg Tablet
D-Glip 5mg Tablet
Dactovin 60mg Tablet
Dianerve Capsule
Diazox 50 mg/500 mg
Hycef 200mg Tablet
Hycef 50mg Dry Syrup
I Gest 200mg Tablet
I Gest 200mg Tablet SR
I Gest 300mg Tablet
Ilacare Tablet
Ipzact 4000 mg/500 mg Injection
Ironup Capsule
Iscept 2.5 mg/400 mg Tablet
Iscept 2.5mg/500mg Tablet
Iscept Forte 5 mg/800 mg Tablet
Iscept L 1.25 mg/250 mg Tablet
Iscept P 5 mg/500 mg/15 mg Tablet
Izabof 250mg Tablet
Kefotax 1000mg Injection
Kefotax 2000mg Injection
Kefotax 250mg Injection
Kefotax 500mg Injection
Kefotax O 100mg Tablet DT
Kefotax O 100mg/5ml Dry Syrup
Kefotax O 200mg Tablet
Kefotax O 50mg Dry Syrup
Kefotax SB 1000 mg/500 mg Injection
Kefotax SB Injection
Kefotax TZ 1000 mg/125 mg Injection
Levasma 5 mg/10 mg Tablet
Levasme Syrup
Levroxa 1000mg Tablet
Levroxa 250mg Tablet
Enrest 100 Tablet
Enrest 50mg Tablet
Epm 10mg Tablet
Epm 2.5mg Tablet
Epm 5mg Tablet
Ethnorub Gel
Ethnorub MR Gel
Fliptor 10mg Tablet
Fliptor 20mg Tablet
Fliptor 40mg Tablet
Fliptor 5mg Tablet
G Clox 500mg Tablet
G Clox 500mg Tablet
G Clox 750mg Tablet
G Clox Infusion
G Sinux Tablet
G Ten 100mg Tablet
G Ten 50mg Tablet
Gefer Forte Injection
Gefer Injection
Gefer XT Tablet
Gibiotic Capsule
Glicept 2.5mg/400mg Tablet
Glicept 5mg/500mg Tablet
Glim 40mg/500mg Tablet
Glim 80mg/500mg Tablet
Glybose 0.2mg Tablet
Glybose 0.3mg Tablet
Glybose M 500 mg/0.2 mg Tablet
Glybose M 500 mg/0.3 mg Tablet
Gofolate Plus Tablet
Gofolate Tablet
Grafix 100mg Tablet DT
Grafix 200mg Tablet DT
Grafix 50mg Dry Syrup
Hycef 100mg Tablet DT
Capsule
Renerve Softgel Capsule
Renerve-G 100mg/500mcg Capsule
Renerve-G Capsule
Renewliv P Tablet
Renewliv Sachet
Levroxa 500mg Tablet
Levroxa 750mg Tablet
Levroxa Syrup
Lopih 100mg Tablet
Lorisk 10mg/160mg Tablet
Lorisk Tablet
Lorisk Tablet
Lotgl 200mg Tablet
Maxitor Tablet
Megaza Capsule
Myo MR Plus Tablet
Myo-MR 150mg Tablet
Myo-MR OD 450mg Tablet
Myoheal D Tablet
Myoheal Tablet
NBP 2.5mg Tablet
Neodipine 10mg Tablet
Neodipine 20mg Tablet
Neodipine 5mg Tablet
Neodipine M Tablet
Neodipine T 10mg/40mg Tablet
Nervepen Gel
Neugalin 50 Capsule
Neugalin 75mg Capsule
Nmd 150mg Tablet
Nmd 50mg Tablet
Nmd Plus Syrup
Nmd Plus Tablet
Nocaf Expectorant
Nuprin 200 Tablet
Nuprin 300mg Tablet
Nuprin Plus Tablet
Raricap 100 Tablet
Raricap CT Tablet
Raricap Combi Tablet
Raricap Drops
Raricap Forte Tablet
Raricap L Suspension
Raricap M Tablet
Raricap S 100mg Injection
Raricap Tablet
Recognix 500mg Injection
Recognix 500mg Tablet
Retinokare Capsule
Rhinoday 10 mg/120 mg Tablet
Riv 20mg Injection
S Camlo Tablet
Serlift 100 Tablet
Serlift 25 Tablet
Serlift 50 Tablet
Setronem 2mg Injection
Setronem 4mg Tablet
Setronem 8mg Tablet
Sorest 100 Tablet
Sorest 50mg Tablet
Spasfree 80mg/100mg Tablet
Starflu 75mg Capsule
Stricept 250mg Capsule
Stricept 500mg Capsule
Stugil D Tablet
THT D 40mg/12.5mg Tablet
Telanin 200mg Injection
Telanin 400mg Injection
Tht 20mg Tablet
Tht 40mg Tablet
Tom 20mg Tablet
Tom FT 20mg Tablet
Tramdol Injection
Trimester Tablet
Triplet 1 mg/500 mg/15 mg Tablet
Triplet 2 mg/500 mg/15 mg Tablet
Twool 200 mg/500 mg Tablet
Twool 50mg/5ml/125mg/5ml
Suspension
Vazo Gel
Vazocap 250 mg/250 mg Capsule
Vcandi Gel
Vibrex 20mg Tablet
Vibrex 40mg Tablet
Virpas Tablet
Virso Tablet
Wound Fix Solution
Injection
Diazox 50 mg/500 mg Tablet
Diazox Aqua 25mg/75mg
Obilix 120mg Capsule
Recognix Syrup Obilix 60mg Capsule
Renerve 1mg Injection Ocin PD 50mg/5ml Syrup
Renerve 24 Capsule Olanex Plus 10 Tablet
Renerve B T Capsule Olanex Plus 5 Tablet
Renerve D Tablet Olfamist Nasal Solution
Renerve Forte Capsule Pantom FT 40mg Tablet
Renerve Max Capsule Polynerve Capsule
Renerve P 750mcg/75mg Capsule Polynerve NT Tablet
Renerve P SR Tablet Polynerve OD Capsule
Renerve Plus BT Capsule Prodixdha Tablet
Renerve Plus Injection Prolina OG Powder
Renerve Plus Softgel Pye 15mg Tablet
Opiprex 100mg Tablet Pye 30mg Tablet
Opiprex 50mg Tablet R DSR Capsule
Ortholix 50 mg/750 mg Tablet Pantom 40mg Injection
Ortholix AC Tablet Pantom 40mg Tablet
Pantom DSR Capsule
Pye M 15 mg/500 mg Tablet
R DSR Capsule

SERVICES OF STRIDES

Proof of concept
New ideas for novel drug delivery dosage from services beings through broad
spectrum technology platforms.
Our development models for POC studies are widely recognized for speed, precision,
innovation
With scalable feasibility for the full spectrum of studies. Based on the client needs
and regulations R&D
Team evaluate number of technology parameters for the development and
manufacturing capabilities of Specific API / salt/ polymorphic (active pharmaceutical
ingredient) dosage forms using significantly Smaller scale R&D batches.

Analytical services
Strides analytical group has a diverse background in analytical method development
and in –depth
Understanding of all facets of the drug development process. As your strategic
development partners,
We design detailed protocols for method development, validation and technology
transfer based on the product’s phase in the drug development, validation and
technology transfer based on the
Product’s phase in the drug development process.
Analytical capabilities:

 Characterization of API
 Analytical Method Development
 Impurity profiling
 Solubility Studies
 Dissolution Studies / Dissolution Method Development
 Multi-Media Dissolution
 Polymorphic studies
 Photo stability
 Microbiological Testing
 Analytical Method Validation and Report

Clinical Manufacturing

With our long as a pharmaceutical manufacturer, every project receives the highest
quality with the quality with the greatest efficiency and speed possible. We proudly
provide uncompromising performance backed by intellectual distinction, top of the
line equipment and state of the art processing. Strides R&D has a strong team for the
design execution and analysis towards every projects.

The BE team work closely with the formation, Analytical and regulatory teams for the
designing and execution of the bio equivalence studies and compilation of the
Dossiers. We also co-ordinate with various National and International Clinical
Research organization inspected by regulatory agencies like USFDA, UK, MHRA,
WHO, ANSM, AVISA with their experts and project management team for the timey
execution of the bio equivalence studies. We are responsible for the complete Bio-
pharmaceutics, clinical pharmacology and pharmacokinetics review. Every year we
conduct sizeable number of studies. Various types of study designs are adopted
depending upon the complexities of the drug product for the conduct of the pilot and
pivotal studies. The commonly adopted study designs are single dose two-way
crossover studies, Partial and fully replicated studies and multiple dose studies.

Commercial Manufacturing

The facilities are approved by various regulatory authorities including North

America,USFDA, UK MHRA, TGA AUSTRALIA, HEALTH CANADA, PMDA
japan, MFDS South korea, MCC South Africa, and ROW markets of Africa.
All the manufacturing facilities have unidirectional flow of man and Materials,
Movement and capable to manufacture various dosage forms like Tablets, Capsules
dry powders for suspension, dry powder for injection etc…. Under stringent GMP
environment conditions. The facilities are qequipped with latest equipment’s to
manufacture the products as per the international regulatory standards. All the units
operate under Quality Management System(QMS) as per International guidelines and
Eqms system has been implemented to facilitate the QMS for continuous
improvement. All plants have Independent full-fledged quality control laboratories
which consists on instrumentation, chemical, microbiological and packaging material
testing section. Quality control operation are handled through Quality Laboratory
Management System (QLMS) enabling direct capture of data from equipment ot
materials, packing materials and finished goods as per the storage condition
requirements. Two stability centers equipped with walk in chambers to perform
stability studies for all the zones as per ICH guidelines. The entire operations from
the environment health and safety(EHS) measures are inplace as per global standards.
Facilities are equipped with effluent treatment plant, fire hydrants system, Emergency
Response plan, to provide a safe and healthy working environment. Dedicated
operational excellence team (OE) in place for continuous improvement through tools
like six sigma, kaizen etc.

Formulation Development

Strides has extensive experience and strong expertise in the timely development of
OSD(Oral Solid Dosage forms) including modified, controlled and FDC immediate
direct powder formulations. Formulations development process capabilities include
direct powder blending, high shear granulation, bottom spray fluid bed granulation
twin screw melting granulation, dry roller-compaction, bi-layer / MUPS compression,
multi components capsule filling and powder for reconstitution in sachet – bottle
packs. Other formulation –Liquid syrup, suspension, emulsion, semisolid ointment,
creams technology development and transfer to manufacturing site capabilities are
also available on clearly agreed objectives.

Packaging Design and Development

Strides packaging team is continuously working to preserve the quality, potency and
safety of the pharmaceutical products through the intended shelf life. The tea
develops primary and secondary packaging complying with all the customer and
regulatory requirements for various dosage forms like Tablets, Capsules, Oral
solutions / suspensions, Syrup, Injection Sachets and ophthalmic preparations. Strides
has dedicated packaging capability which can handle different type of packing
configuration like blisters ( handling PVC/PVDC/ACLAR/PP & Alu-Alu), blisters in
pouch, tropical blister, strip, child resistant blister, bottle with CRC & screw cap,
injectable followed by automated secondary packaging which also supports pharma
code reading, anti-counterfeit features meeting customer and country specific
requirements.
Artwork and labeling functions are an intrinsic part for the supply of a pharmaceutical
product, and are fully capable to meet customers and regulatory requirements. The
packaging team is equipped to handle numerous artworks with the concept of right
first time with project management, repository management with version control. The
team has capability of designing packaging with both overt and covert anti-counterfeit
features. We work closely with our customers to gather inputs while developing and
finalizing its packaging case, pallet specification.
2.5 OWNERSHIP PATTERN OF STRIDES

Arun Kumar Group CEO & Managing Director

Group CEO & Managing Director
Arun is appointed as Executive Chairman effective April 1, 2018.

Deepak Vaidya Non-Executive Director and

Chairman of the Board
Appointed to the Board in January 16, 1998

S. Sridhar independent Director

Appointed to the Board on July 27, 2012

Homi rustomKhusrokhan

Appointed to our Board on May 18, 2017

Bharat D.shah independent Director

Appointed to the Board on July 25, 2014

Sangita Reddy independent Director

Appointed to the Board on February 7, 2014

Shashank Sinha – CEO

International Business
 Badree Komandur
Executive Director - Finance

Dennis Bastas
Executive Chairman- ARROW Pharmaceutical Australia

Mohan kumar – CEO & Managing Director

Strides Pharma Global

Gabriel Richard Simaan

Managing Director – Trinity Pharma

Perviz Dhanani
Managing Director – Universal Corporation Ltd
Kenya

Kevin Knarr - Vice President

Strides Pharma Inc

Mohan Devneni - President

Technical Strides Pharma Inc

Sohel Islam – Head sales

Strides Pharma UK ltd
2.6: ACHIEVEMENTS AND AWARD ;
1. THE ECONOMIC TIMES INDIA MANUFACTURING EXCELLENCE AWARD
2014

2. BEST MANUFACTURING EXPORTER AWARD 2016

3. INDIA MANUFACTURING EXCELLENCE AWARD 2015

2.7 : FUTURE GROWTH AND PROSPECTUS
 Strides ha more than 2000 employees located worldwide with a client base
that spread across 51 subsidiaries (46 overseas and 5 in India) 3 Joint Ventures
(2 overseas and 1 in India) and 4 associate companies (3 overseas and 1 in
India). As part of the pharma industry, “Quality” is the cornerstone of our
business.
 We are dedicated to the development of individual through on-the-job and off-
the-job training programs both within and outside India. We provide equal
opportunities to all employees irrespective of their background, ethnicity and
culture. Strides has Multiple Talented Management Programs to objectively
identify, assess and nurture the talent pool in the company to meet the future
needs. There are well defined career progression roadmaps for high potentials
too.
Expect our employees to contribute to the organization through ideas, develop
their capability and competence, deliver high performance and live the value
of “winning culture ”
 Leverage a robust ‘go to market’ capability to expand distribution network
across Australia, the North American nation and therefore the GB.
 Strides have signed a 10-year exclusive contract with letter, largest wholesale
distributor.
 Strides are facilitating new development, as well as medication going off-
patent through the acquisition of generic partners.
 Strides are increasing loyalty and substitution at individual Pharmacy levels
through Pharmacy Alliance.
 Strides are specializing in producing consolidation below the United Nations
agency approved facility in African nation and dedicated rising market plant in
India.
 Where Strides provide large pool of job opportunity to the pool of qualified
employees and provide proper guidelines and helps them by pushing
towards professional growth.

The following are the expansion driver that is sanctionative the expansion prospectus
of the company:
• Quality compliance
• price focus
• R&D execution
• established management team
• Winning culture
 CHAPTER – 3
MCKINSEY’S 7S
FRAME WORK
3.MCKINSEY’S FRAMEWORK WITH SPECIAL REFERENCE
TO ORGANIZATION UNDER STUDY

1.STRUCTURE : Structure is similar to the skeleton to eh entire association. The

formal relationship among different position and exercise. The organization structure
at Strides ltd is decentralized and authorization of power and responsibilities is
assigned to various departmental heads such as Engineering, HR, Sales, Production,
packing, Quality check, Quality assurance and R&D. The supporters to heads of the
department are assigned the job of aiding the Heads, They are call Assistant
Managers, Assistant stores Manager, Executive personal.
 PLANT HEAD

Sr.
Engineering Store Sr. HR
production
Manager Manage Manager
Manager

Assistant Asst. Executive Executive

Stores
Manager Personal Manager
Manager

Executive Executive Assistant Office

Stores Personal Manager

Engineering

STRATEGIES
Strategies refer to a set of actions that company start with and must maintain. It
includes integrated vision and direction of the company in which it desires,
communicates and builds a relationship with implementation of vision and direction.
A blend of manufacturing, research and development, documentation services, deep
insights in the pharmaceutical domain, enduring partnership, and above all the passion
to win, translates into the Strides advantage in the area of the quality, innovation,
value addition and every time on time deliveries. This Quality of Strides acts as the
strategy which enables the company to face the stiff completion and increase its
sustainability in the market
STAFF
Working together as a team by keeping our eyes and ears firmly on the objective and
focusing on that, we can hope to become a Winning together organization, and shape
a better future. People power is what makes Strides a achieving company. Strides
management team is experienced; people-centred and responsible to its stakeholder
and client based, follows a strict code of business Ethics and is focused on taking the
company to greater heights.

As a company, Strides is committing to being the employer of choice by inspiring,

nurturing and empowering its people and ensuring that every employee’s leadership
qualities are fully developed.

SHARED VALUES
 Value statement denotes the behavior
 value statement is specific at the same time so descriptive it leaves little to
imagination
 value statement is how the mission and means to an end
 value statement defines the way how we behave, work and interact

SKILLS
This pharmaceutical industry employs a broad range of specialist skill sets across all
scientific and commercial disciplines. This does make the sector and exciting and
attractive one to be part of, but also a highly challenging industry to ensure the `right
talent are in the right places. An example of some the specialist skill sets which we
support the recruitment for include.

 Regulatory affairs (30+ regulatory experts capable of undertaking regulatory

filings)
 Quality Assurance (including Qualified persons)
 Research and Development
 Excellence in beta lactams, various combinations
 Global Generics marketing and distribution
 10+ years experience in Africa, tie up with GSK
 Preferred supplier to major south Africa players

SYSTEMS
Automated storage and Retrieval system (ASRS)
With the challenges in mind, the Strides team decided to connect all locations in the
new facility’s manufacturing and warehouse areas via a fully integrated automated
storage and retrieval system
(ASRS) “ASRS are available in several manufacturing facilities, but this plant
connected the system into manufacturing operations with a network of conveyors and
automated lifts.
When a person in the manufacturing area makes a request on a computer, the material
will picked up from the warehouse and delivered to that particular location and that
particular floor. That gives a great relief to the manufacturing personnel from the
supportive activities. This is especially helpful during evening or night shifts, when
fewer staff may be available and moving materials across the plant becomes more
challenging.

Corporate Social Responsibility :

As a Pharmaceutical Company, we are socially responsible and conscious about the
interest of all the key stakeholders and involving community at large in general. We
aim to work harder to win and retain their trust. The involvement plans has been
created with an objective of meeting socio economic, healthcare, Environmental
Health and Safety requirements of local community with significant engagement
initiatives in such a way to give priority to be responsible Corporate.

Strides believes in the policy of providing healthcare and more specifically preventive
healthcare that is beneficial to the needy of the society who cannot afford expensive
medical treatment at large, by providing timely and advanced healthcare and other
medical facilities to all in its local area of operations with a vision to create an
environment which enables to execute the direction HEALTH FOR ALL.

STYLE :
Style is of the seven levels which top control can use to bring about organizational
changes. The styles of an undertaking in accordance with the Mckinsey’s frame work
will become obvious through the pattern of action taken with the aid of contributors of
the best control assemble over a time period. The parts of the business by methods
for human beings down the employer reporting connections may furthermore convey
the style of the organization.

persons encourages participative administration style to guarantee quality and safe

items. It includes every one of the representatives, temporary workers, advisors,
business partners and others.

Participative leadership style of best administration:

 Maintain discipline inside the organization.

 Gives directions and orders to the subordinates.
 Listened to subordinates and reacts to their desires.
 Takes critical choices for the institution .
 Maintain unity in the company.
 Inspires and inspires the various people of the organization.
 Encourage , Motivate, to achieve standard objective
 Attain or plan focuses for his organizations.
 Maintain discussion inside the office.
 CHAPTER – 4
SWOT ANALYSIS
 CHAPTER - 4
SWOT ANALYSIS

3. SWOT ANALYSIS

STRENGTHS
 Working environment is constructive for both personal and professional
growth.
 Customer focus and rapid response
 Strong R & D product platform to introduce new product
 Large pool of highly trained manpower
 Good relationship with global marketing companies
 Product innovation, manufacturing, operational flexibilities.
 Follow procedures and regulatory requirements.

WEAKNESS
 Delay in product approvals
 Operation cost is high.
 Maintenance cost is very high.
 Poor marketing network has resulted in less advertisement for the capsules
manufactured.
 Government price controls
 High tariffs and taxes
OPPORTUNITIES

 New treatment regimen attracting the acting donor funding.

 Global partnerships with the likes of Pfizer, GSK and Asken etc.
 Significant investment in organic and inorganic expansion.

THREATS
 Competitions from the domestic as well as the global players.
 Emergence of new entrants
 Delay in the regulatory approvals may increase competition and thereby
reduce profitability of strides.
 Uninterrupted supply of raw material, companies operational cost risk will
dampen the profitability of the business
 CHAPTER – 5
ANALYSIS OF THE
FINANCIAL
STATEMENTS
 CHAPTER – 5
ANALYSIS OF FINANCIAL STATEMENT
Balance Sheet of Strides Pharma Science ltd as on …...........(Rs in Crores)
Particulars Mar’18 Mar’17 Mar’16 Mar’15
Liabilities 12 Months 12 Months 12 Months 12 Months
Share capital 89.64 89.42 89.35 59.62

Reserve & Surplus 3012.97 3143.10 3046.06 1414.81

Net Worth 3162.02 3232.53 3135.41 1474.42

Secured loans 604.04 1416.89 1425.11 326.90
Unsecured loans 00 00 00 00
Total liabilities 3766.05 4649.42 4560.52 1801.33
Assets
Gross block 613.12 1289.16 1653.85 586.33

(-)Acc. Depreciation 155.16 165.40 595.02 191.88

Net block 497.96 1123.76 1085.86 394.50

Cap. Work in progress 209.85 227.82 180.09 39.10
Investment 1776.67 2520.24 2366.87 968.46
Inventories 296.63 409.59 379.23 155.40

Sundry debtors 449.37 540.68 702.29 256.01

Cash & Bank 79.79 94.92 94.34 94.30

Loan & Advances 1001.84 564.28 582.34 276.03
Total current Assets 1800.68 1609.41 1758.21 761.74
Current Liabilities 478.95 783.36 741.96 304.60
Provision 40.16 48.46 62.01 57.87
Total Current Liabilities 519.11 831.82 803.47 362.47

Net Current Assets 1281.57 777.60 954.74 399.27

Miscellaneous Exp. 00 00 00 00
Total Assets 3766.05 4649.42 4560.52 1801.33
(A+B+C+D)
 Profit & loss Account – Strides Pharma Science ltd.
For the year ending…….....

Particular Mar’18 Mar’17 Mar’16 Mar’15

12 Months 12 Months 12 Months 12 Months
INCOME
Sales turnover 1469.61 1381.82 2261.28 933.10
Excise duty 00 00 57.79 3.69
NET SALES 1469.61 1381.82 2203.49 929.42
Other income 156.1790 169.0550 140.9610 100.176
Total income 1625.81 1550.87 2344.45 1029.59
EXPENDITURE
Manufacturing Exp. 33.08 25.82 74.70 13.00
Material Exp. consumed 826.05 776.33 1254.72 516.24
Personal Exp. 224.53 228.48 274.97 120.20
Selling Exp. 00 00 15.16 00
Administrative Exp. 185.85 180.47 301.88 146.07
Expenses capitalized 00 00 00 00
Provision Made 00 00 00 00
Total Expenditure 1272.52 1211.10 1921.43 795.50
Operating Profit 197.09 170.72 282.06 133.92
EBITDA 353.29 339.77 423.02 234.10
Depreciation 77.81 70.01 105.85 49.25
Other write-off 00 00 00 00
EBIT 215.48 269.77 317.17 187.84
Interest 81.97 71.96 102.71 34.42
EBT 193.51 197.81 214.46 150.42
Taxes 705.76 -58.56 -25.18 518.61
Profit & loss for the Yr 185.83 167.09 186.25 13.71
Non-recurring items -705.76 -58.56 -25.18 518.61
Other Non-Cash 00 00 00 00
Adjustment
Reported PAT 897.59 108.54 161.07 532.32
KEY ITEMS
Preference dividend 00 00 00 00
Equity dividend 47.82 43.23 33.58 597.28
Equity dividend (%) 53.43 48.33 374.57 1001.87
Share in isuue (Lakhs) 895.00 894.23 893.46 596.16
EPS-Annualized (Rs) 99.62 12.14 18.03 89.29
RATIO ANALYSIS

 CURRENT RATIO
Current ratio = Current Assets / Current liabilities
Current Ratio is defined as the link between current assets and current
liabilities. It is also called as working capital ratio, generally it helps to
measure liquidity and it is widely used to make the analysis of a short term
financial position or liquidity of a firm .

TABLE 5.1 CURRENT RATIO

Years Current assets Current liabilities Current ratio

2018 1800.68 478.95 3.759

2017 1609.41 783.36 2.054
2016 1758.21 741.96 2.369
2015 761.74 304.60 2.500

Chart No 5.1 Current Ratio

3.5

2.5

1.5

0.5

0
2018 2017 2016 2015
Current ratio 3.759 2.054 2.369 2.5

INTERPRETATION: There is continuous fluctuation in the current ratio, in the

year 2018 the highest value is 3.759 times which is decreased in 2017 to 2.054 times
and further increased and the value in the year 2016 is 2.369 times and further a bit of
increased in the year 2015 is 2.500 times. It shows that the current assets are
fluctuated in the period 2018-2015. Hence , it does not match with set standard.
  QUICK RATIO
Quick ratio = Quick Assets / Current liabilities
Quick assets = Current assets – (Stock + prepaid expenses)
It might be characterized as the relationship between quick/liquid assets
resources and current liabilities. It is also called as financial ratio which helps
to calculate company liquidity position. And it may also as acid test ratio.

TABLE 5.2 QUICK RATIO

Years Quick asset Current liabilities Quick ratio

2018 1504.05 478.95 3.140

2017 1199.88 783.36 1.531
2016 1378.98 741.96 1.858
2015 606.34 304.60 1.990

Chart NO 5.2 Quick Ratio

3.5

2.5
Axis Title

1.5

0.5

0
2018 2017 2016 2015
Quick Ratio 3.14 1.531 1.858 1.99

INTERPRETATION:

There is a variation in the quick ratio, in the year 2018 the quick ratio is 3.14 times
which is decreased in 2017 to 1.531 times and further increased and the value at the
year 2016 is 1.858 and also further a bit of value is increased in the year 2015 is to
1.99 times. It shows that quick assets are continuously fluctuated in the period 2018-
2015. The standard ratio does not match with set of standard.
  TOTAL ASSETS TURNOVER RATIO
Total asset turnover ratio = Net Assets / Total Assets

The asset turnover ratio is an efficiency ratio that measures a company’s

ability to generate sales from its assets by comparing net sales with average
total assets. This ratio shows how efficiently a company can use its assets to
generate sales.

TABLE 5.3 TOTAL ASSETS TURNOVER RATIO

Years Net Sales Total assets Total assets turnover
ratio
2018 1469.61 3766.05 0.390
2017 1381.82 4649.42 0.297
2016 2203.49 4560.52 0483
2015 929.42 1801.33 0515

Chart No 5.3 Total Assets Turnover ratio

0.6

0.5

0.4

0.3

0.2

0.1

0
2018 2017 2016 2015
Total assets turnover ratio 0.39 0.297 0.483 0.515

INTERPRETATION:
There is changes in total assets turnover ratio , in the year 2015 the total assets
turnover ratio is 0.515 times which is decreased in 2016 i.e. 0.483 times and further
decreased in the year 2017 is 0.297 times and further increased in the year 2018 is
0.390 times. It shows that the total assets are fluctuated in the period 2018-2015. The
standard total assets turnover ratio does not match with set standard
  FIXED ASSETS TO NET WORTH RATIO
Fixed assets to net worth ratio = Fixed Assets
Net worth
Fixed assets to net worth is a ratio measuring the solvency of a company. This
ratio indicates the extent to which the owner’s cash is frozen in the form of
fixed assets, such as property, plant and equipment and the extent to which
funds are available for the company’s operation (i.e. for working capital)

TABLE 5.4 FIXED ASSETS TO NET WORTH RATIO

Years Fixed assets Net worth Fixed assets to Net
worth ratio
2018 497.96 3162.02 0.157
2017 1123.76 3232.53 0.347
2016 1058.83 3135.41 0.337
2015 394.50 1474.42 0.267

Chart No 5.4 Fixed Assets To Networth Ratio

0.35

0.3

0.25

0.2

0.15

0.1

0.05

0
2018 2017 2016 2015
Fixed Assets to Net worth ratio 0.157 0.347 0.337 0.267

INTERPRETATION:

There is changes in the fixed assets to net worth ratio, in the year 2018 the fixed assets
to net worth ratio is 0.157 times which is increased in 2017 is 0.347 times and further
decreased and the value at the year 2016 is 0.337 times and further decreased in the
year 2015 is at 0.267 times. It shows that the fixed assets are fluctuated in the period
2018-2015. The set standard of fixed assets is not satisfactory.
  CURRENT ASSETS TO NET WORTH RAITO
Current assets to net worth ratio = Current Assets
Net worth
It is the ratio between current assets and net worth of an organization.
Generally, it is interpreted as more the ratio more will be the solvency.
And as such there is no idle or standard Current assets to net worth ratio.

TABLE 505 CURRENT ASSETS TO NET WORTH RATIO

Years Current assets Net worth Current assets to
Net worth ratio
2018 1800.68 3162.02 0.508
2017 1609.41 3232.53 0.497
2016 1758.21 3135.41 0.560
2015 761.74 1474.42 0.516

Chart No 5.5 Current Assets Networth Ratio

0.56
0.55
0.54
0.53
0.52
0.51
0.5
0.49
0.48
0.47
0.46
2018 2017 2016 2015
Current assets Networth ratio 0.508 0.497 0.56 0.516

INTERPRETATION:

There is fluctuation in the current assets to net worth ratio in the year 2018 the current
assets to net worth ratio is 0.508 times which is decreased in the year 2017 is 0.497
times and further increased and the value at the year 2016 is 0.560 times and further
decreased in the year 2105 is 0.516 times. It show the current assets are fluctuated in
the period 2018-2015.
  FIXED ASSETS TURNOVER RATIO
Fixed assets turnover ratio = Net sales
Fixed Assets
The fixed assets turnover ratio is an efficiency ratio that measures a
company’s returns on their investment in property, plant and equipment by
comparing net sales with fixed assets. It calculates how eddciently a company
is producing sales with its machines and equipment.

TABLE 5.6 FIXED ASSETS TURNOVER RATIO

Years Net assets Fixed assets Fixed assets turnover
ratio
2018 1469.61 497.96 2.951
2017 1381.32 1123.76 1.229
2016 2203.49 1058.83 2.081
2015 929.42 394.50 2.355

Chart No 5.6 Fixed Assets Turnover ratio

2.5

1.5

0.5

0
2018 2017 2016 2015
Fixed Assets Turnover ratio 2.951 1.229 2.081 2.355

INTERPRETATION:

There is fluctuation in the fixed assets turnover ratio, in the year 218 the fixed assets
turnover ratio is 2.951 times which is decreased in 2017 i.e. 1.229 times and further
increased and the value at the year 2016 is 2.081 times. And further increased in the
year 2015 is 2.335 times. It shows that the fixed assets are fluctuated in the period
2018-2015. The standard fixed asset turnover ratio does not match with set standard.
  CURRENT ASSETS TURNOVER RATIO
Current asset turnover ratio = Net sales
Current Assets
Current assets turnover ratio shows the relationship between net sales and
current assets. We divide the net sales with current assets.

TABLE 5.7 CURRENT ASSETS TURNOVER RATIO

Years Net sales Current assets Current asset
turnover ratio

2018 1469.61 1800.68 0.816

2017 1381.82 1609.41 0.858
2016 2203.49 1758.21 1.253
2015 929.42 761.744 1.220

Chart No 5.7 Current Assets Turnover Ratio

1.4

1.2

0.8

0.6

0.4

0.2

0
2018 2017 2016 2015
Current Assets Turnover Ratio 0.816 0.585 1.253 1.22

INTERPRETATION:

There is fluctuation in the current assets turnover ratio, in the year 2018 the current
assets turnover ratio is 0.816 times which is decreased in 2017 i.e. 0.585 times and
further increased and the value at the year 2016 is 1.253 times and further a bit of
decreased in the year 2015 is 1.220 times. It shows that the current assets are
fluctuated in the period 2018-2015. Higher ratio higher the efficiency.
  PROPRIETARY RATIO
Proprietary ratio = Shareholders Fund
Total Assets
The proprietary ratio ( also known as net worth ratio or equity ratio) is used to
evaluate the soundness of the capital structure of a company. It is computed by
dividing the stockholder’s equity by total assets.

TABLE 5.8 PROPRIETARY RATIO

Years Shareholders fund Total Assets Proprietary ratio
2018 3162.02 3766.05 0.839
2017 3232.53 4649.42 0.695
2116 3135.41 4560.52 0.687
2015 1474.42 1801.33 0.818

Chart No 5.8 Proprietary Ratio

0.9

0.8

0.7

0.6
Axis Title

0.5

0.4

0.3

0.2

0.1

0
2018 2017 2016 2015
Proprietary Ratio 0.839 0.695 0.687 0.818

INTERPRETATION:

There is fluctuation in the proprietary ratio, in the year 2018 the proprietary ratio is
0.839 times which is decreased in 2017 and 2016 is 0.695 to 0.687 times and further it
has increased the value at the year 2015 is 0.818 times. It shows that shareholders
fund is fluctuated in the year 2018-2015.
  NET PROFIT RATIO
Net Profit ratio = Net Profit___________________ * 100
Revenue from operation(Net sales)
Gross profit ratio indicates the trading results of an organization. This indeed
does not reflect the overall profitability position of an organization. Hence net
profit ratio is essentially required in decision making. Net profit ratio is ratio
between net profit and revenue from operations of an organization.

TABLE 5.8 NET PROFIT RATIO

Years Net profit Revenue from Net profit ratio
operations (Net sales)
2018 185.83 1469.61 12.644
2017 167.09 1381.82 12.092
2016 186.25 2203.49 8.452
2015 13.17 929.42 1.475

Chart No 5.9 Net Profit Raito

14

12

10

0
2018 2017 2016 2015
Chart No 5.8 Net Profit Raito 12.644 12.092 8.452 1.475

INTERPRETATION:

The above table shows that, in the year 2015 the company is suffering from loss i.e.
1.475 and the next financial year 2016 it has recovered the losses i.e. 8.452. In the
year 2017 the value is increased to 12.092 compare to previous. And in the year 2018
the value is increased to 12.644 compare to previous years, currently the company is
recovering towards profit.
TREND ANALYSIS
A trend analysis is an aspect of technical analysis that tries to predict the future
movement of a stock based on past data. Trend analysis is based on the idea that what
has happened in the past gives traders an idea of what will happen in future.

Balance sheet of strides ltd as on………………….

Particulars Mar’16 % Mar’17 % Mar’18 %
Liabilities 12 Months 12 Months 12 Months
Share capital 89.35 100 89.42 100 89.64 100
Reserve & 3046.06 100 3143.10 97 3012.97 101
Surplus
Net Worth 3135.41 100 3232.53 97 3162.02 99
Secured loans 1425.11 100 1416.89 100 604.04 236
Unsecured loans 00 00 00 00 00 00
Total liabilities 4560.52 100 4649.42 98 3766.05 121
Assets
Gross block 1653.85 100 1289.16 128 613.12 269
(-)Acc. 595.02 100 165.40 359 155.16 383
Depreciation
Net block 1085.86 100 1123.76 96 497.96 218
Cap. Work in 180.09 100 227.82 79 209.85 86
progress
Investment 2366.87 100 2520.24 94 1776.67 134
Inventories 379.23 100 409.59 92 296.63 127
Sundry debtors 702.29 100 540.68 130 449.37 156
Cash & Bank 94.34 100 94.92 99 79.79 118
Loan & 582.34 100 564.28 103 1001.84 58
Advances
Total current 1758.21 100 1609.41 109 1800.68 98
Assets
Current 741.96 100 783.36 95 478.95 155
Liabilities
Provision 62.01 100 48.46 127 40.16 154
Total Current 803.47 100 831.82 96 519.11 155
Liabilities
Net Current 954.74 100 777.60 123 1281.57 74
Assets
Miscellaneous 00 00 00 00 00 00
Exp.
Total Assets 4560.52 100 4649.42 98 3766.05 121
(A+B+C+D)
INTERPRETATION:
Liquidity position:
A measure of the extent to which an organization has cash to meet
immediate and short term obligations, or assets that cha be quickly converted to this,
i.e. The ability of current assets to meet current liabilities. The ability to quickly
convert an investment portfolio to cash with little or no loss in value.

The liquidity position in 2017 is better than the previous year 2018. It is because
current assets of the current year have increased to 123% as compared with 2018
which was of 74%. In case of current liabilities of 2018 which of 155% where as in
case of previous year it is 96%. It means the organization is in a comfortable position
to meet its short term obligations and is favourably capable of maintaining the
liquidity position.

Solvency position:
Solvency is the ability of company to meet its long term financial
obligations. solvency is essential to staying in business as it assets a company’s ability
to continue operation into the foreseeable future.
The decrease in fixed assets especially is an indication of the organization plans for
maintaining the stability in its performance which can also be noticed through
consistency in the ownership funds. /This means the organization is trying to strive a
balance between debt and equity, through its investment activity which is higher in
2018 i.e. 134% which has increasing trend when compared with that of the year 2017
which is of 94%. This approach is to be appreciated as it is an act of maintaining the
stability though there is a slight changes in values.

Profitability ratio:
Profitability is the ability of a business to earn a profit. A profit is
what is left of the revenue a business generates after it pays all expenses directly
related to the generation of the revenue, such as producing a product, and other
expenses related to the conduct of the business activities.
The reserve and surplus of the year 2018 is higher in percentage i.e. 101% compared
to the year 2017 which is 97% which clearly indicates that there is an appreciable
progress of the company when compared with the previous year.

CONCLUSION

Based on the above interpretation it is absolute to state that the year 2018 is placed
with favourable performance compared to previous years 2017 and 2016 on the basis
of all the criteria.
 CHAPTER – 6
LEARNING EXPERIENCE
 CHAPTER – 6

LEARNING EXPERIENCE
During my work experience at Strides pharma science ltd. I was fortunate enough t
have experience and learned, many different sides of what goes into a project, the
general process of how departments at different levels works, developed and
completed; as weel as how much and detail goes into every stage of it. Another
valuable lesson I have learned during these 4 weeks. were the many different types of
work an individual has to perform, which in turn, have provided me with more insight
into the different types of role and responsibilities that I could perform, as an MBA.

Reflecting back to my first day at Strides ltd, it was one of the most memorable days
of my time at work. After being introduced to everyone, I was handed an act of
observation to look into. They were very open and happy for me to contribute as
much as I wanted to, and were open to any suggestion and ideas. This instantly made
me feel comfortable and definitely made me feel as though I’m happy to say that, I
have gained insights into the working environment, That gave me an opportunity to
develop with well versed relationship building with the personnel.

Overall, my work experience at Strides ltd was positive. I was very happy with the
amount of things that I have learned and experienced in the 4 weeks of being a student
learner with the company. I believe theat Visvesvaraya Technological University
should keep this aspect of the MBA course as it does provide students with the
experience needed in order to find a job later on ( Even if the experience is over a
short amount of time). I ended up learning a lot more than I thought I would be able to
in the time span. The training has exposed me to many facts of an organization an also
helped me to gain practical knowledge, which will go a long way in the horizon of my
career.
BIBLIOGRAPHY
REFERENCE
 FUNDAMENTALS OF ACCOUNTING - R NARAYANA SWAMY.
A Managerial Perspective, PHI Publications, 5th Edition.

 ACCOUNTING FOR MANAGERS – J MADEGOWDA

WEB SOURCE

 WWW.STRIDESPHARMASCIENCE .COM
 https://en.wikipedia.org/wiki/Strides_Pharma_Science_Limited
 https://www.business-standard.com/article/companies/strides-pharma-gets-us-
fda-approval-for-hypokalemia-treatment-drug-118090500840_1.html
 http://www.stridesarco.com/pdf/Annual%20Report/annual_report_for_fy_201
7_2018.pdf
 https://www.business-standard.com/company/strides-pharma-
16996/information/company-history
 WWW.ECONOMICSTIMES.COM
ANNEXURE
 Balance Sheet of Strides Pharma Science ltd as on …...........(Rs in Crores)

Particulars Mar’18 Mar’17 Mar’16 Mar’15

Liabilities 12 Months 12 Months 12 Months 12 Months
Share capital 89.64 89.42 89.35 59.62

Reserve & Surplus 3012.97 3143.10 3046.06 1414.81

Net Worth 3162.02 3232.53 3135.41 1474.42

Secured loans 604.04 1416.89 1425.11 326.90
Unsecured loans 00 00 00 00
Total liabilities 3766.05 4649.42 4560.52 1801.33
Assets
Gross block 613.12 1289.16 1653.85 586.33

(-)Acc. Depreciation 155.16 165.40 595.02 191.88

Net block 497.96 1123.76 1085.86 394.50

Cap. Work in progress 209.85 227.82 180.09 39.10
Investment 1776.67 2520.24 2366.87 968.46
Inventories 296.63 409.59 379.23 155.40

Sundry debtors 449.37 540.68 702.29 256.01

Cash & Bank 79.79 94.92 94.34 94.30

Loan & Advances 1001.84 564.28 582.34 276.03
Total current Assets 1800.68 1609.41 1758.21 761.74
Current Liabilities 478.95 783.36 741.96 304.60
Provision 40.16 48.46 62.01 57.87
Total Current Liabilities 519.11 831.82 803.47 362.47

Net Current Assets 1281.57 777.60 954.74 399.27

Miscellaneous Exp. 00 00 00 00
Total Assets 3766.05 4649.42 4560.52 1801.33
(A+B+C+D)
Profit & loss Account – Strides Pharma Science ltd.
For the year ending…….....
Particular Mar’18 Mar’17 Mar’16 Mar’15
12 Months 12 Months 12 Months 12 Months
INCOME
Sales turnover 1469.61 1381.82 2261.28 933.10
Excise duty 00 00 57.79 3.69
NET SALES 1469.61 1381.82 2203.49 929.42
Other income 156.1790 169.0550 140.9610 100.176
Total income 1625.81 1550.87 2344.45 1029.59
EXPENDITURE
Manufacturing Exp. 33.08 25.82 74.70 13.00
Material Exp. consumed 826.05 776.33 1254.72 516.24
Personal Exp. 224.53 228.48 274.97 120.20
Selling Exp. 00 00 15.16 00
Administrative Exp. 185.85 180.47 301.88 146.07
Expenses capitalized 00 00 00 00
Provision Made 00 00 00 00
Total Expenditure 1272.52 1211.10 1921.43 795.50
Operating Profit 197.09 170.72 282.06 133.92
EBITDA 353.29 339.77 423.02 234.10
Depreciation 77.81 70.01 105.85 49.25
Other write-off 00 00 00 00
EBIT 215.48 269.77 317.17 187.84
Interest 81.97 71.96 102.71 34.42
EBT 193.51 197.81 214.46 150.42
Taxes 705.76 -58.56 -25.18 518.61
Profit & loss for the Yr 185.83 167.09 186.25 13.71
Non-recurring items -705.76 -58.56 -25.18 518.61
Other Non-Cash 00 00 00 00
Adjustment
Reported PAT 897.59 108.54 161.07 532.32
KEY ITEMS
Preference dividend 00 00 00 00
Equity dividend 47.82 43.23 33.58 597.28
Equity dividend (%) 53.43 48.33 374.57 1001.87
Share in isuue (Lakhs) 895.00 894.23 893.46 596.16
EPS-Annualized (Rs) 99.62 12.14 18.03 89.29